Ferreira, JJ, Stocchi, F, Antonini, A, Rascol, O, Ebersbach, G, Kulisevsky, J, Fonseca, MM, Ramos, D, Rocha, JF, Brigas, HC, Holenz, J, Poewe, W. Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations. Frontiers in Neurology. 2025; 16DOI:10.3389/fneur.2025.1715748. PMID:41473225. IF:2.800(Q2/5D).

Camacho-Meño, L, Labandeira, CM, Bravo, SB, Torres, MV, Bejr-Kasem, H, Molina-Crespo, A, Atienza, M, Lanciego, JL, Cantero, JL, Kulisevsky, J, Labandeira-Garcia, JL, Rodriguez-Perez, AI. Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson's disease patients. npj Parkinsons Disease. 2025; 12(1)DOI:10.1038/s41531-025-01230-6. PMID:41366251. IF:8.200(Q1/1D).

Kulisevsky, J, García-Ruíz, P, Outeiro, TF, Gurevich, T, Klivènyi, P, Van Laar, T, Milanov, I, Pirker, W, Popescu, BO, Toft, M, Szász, JA. Pharmacogenetics in advanced Parkinson's disease. JOURNAL OF NEURAL TRANSMISSION. 2025; 132(11)DOI:10.1007/s00702-025-03057-0. PMID:41222708. IF:4.000(Q1/2D).

Garcia-Forn, M, Castany-Pladevall, C, Creus-Muncunill, J, Golbano, A, Escaramís, G, Pérez-Pérez, J, Balantzategi, U, Hernan-Godoy, M, Brito, V, Kulisevsky, J, Martí, E, Pérez-Navarro, E. Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients. Neurotherapeutics. 2025; 22(6)DOI:10.1016/j.neurot.2025.e00716. PMID:40774881. IF:6.900(Q1/1D).

García-González, P, Lara, HR, Compta, Y, Fernandez, M, van der Lee, SJ, de Rojas, I, Saiz, L, Painous, C, Camara, A, Muñoz, E, Marti, MJ, Valldeoriola, F, Puerta, R, Illán-Gala, I, Pagonabarraga, J, Dols-Icardo, O, Kulisevsky, J, Fortea, J, Lleó, A, Olivé, C, de Boer, SCM, Hulsman, M, Pijnenburg, YAL, Belloso, RD, Muñoz-Delgado, L, Rueda, DB, Gómez-Garre, P, Aldecoa, I, Aragonés, G, Vara, JH, Mendioroz, M, Pérez-Tur, J, Visser, PJ, den Braber, A, Papma, JM, Montes, AM, Rodriguez-Rodriguez, E, Blázquez-Folch, J, Miguel, A, García-Gutiérrez, F, Cano, A, Valero, S, Marquié, M, Capdevila-Bayo, M, Rosende-Roca, M, Quintela, I, Carracedo, A, Tàrraga, L, Real, LM, Royo, JL, Erro, ME, Guerrero, C, Torres, DC, Blázquez-Estrada, M, San Millán, B, Teijeira, S, Rolan, DV, Hernández, I, Sánchez-Soblechero, A, de la Casa-Fages, B, López, SS, Baviera-Muñoz, R, Lavín, A, Taipa, R, Amer, G, Martinez-Saez, E, Fernández-Matarrubia, M, Lage-Martínez, C, Alvarez, V, Molina-Porcel, L, Holstege, H, Mir, P, Belbin, O, Boada, M, Fernández, V, Bullido, MJ, Rábano, A, Sánchez-Juan, P, Ruiz, A. A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC. EUROPEAN JOURNAL OF HUMAN GENETICS. 2025; 33(7)DOI:10.1038/s41431-025-01872-3. PMID:40379966. IF:4.600(Q1/2D).

Alberti-Vall, B, Olmedo-Saura, G, Domine, M, Borrell-Pichot, M, Avila, MC, Jordana, AV, Pagonabarraga-Mora, J, Kulisevsky, J, Perez, P. Clinical spectrum of anti-IgLON5 disease: A case series with three distinct movement disorder phenotypes. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Toscano-Prat, C, García-Sánchez, C, Ros-Castelló, V, Barguilla-Arribas, A, Saladich, IG, Rodríguez-Clifford, K, Torra-Balcells, R, Boronat, S, Sierra-Marcos, A. Cognitive and neuro-psychiatric profile in adult patients with epilepsy secondary to Tuberous Sclerosis Complex. EPILEPSY & BEHAVIOR. 2025; 166DOI:10.1016/j.yebeh.2025.110380. PMID:40101321. IF:2.300(Q2/4D).

Rodríguez-Antigüeedad, J, Martínez-Horta, S, Puig-Davi, A, Horta-Barba, A, Pagonabarraga, J, Fonticoba, TD, Jesus, S, Cosgaya, M, Caldentey, JG, Avila-Rivera, MA, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Mayordomo, VG, Ardura, JG, García-Soto, JD, Borrué, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Mendoza, Z, Pareés, I, Alonso, PS, Losada, MGA, Ariztegui, NL, Gastón, I, Martínez, JR, Buongiorno, MT, Ordas, C, Valero, C, Puente, V, Kurtis, M, Estrada, MB, Martínez-Martín, P, Mir, P, Santos-García, D, Kulisevsky, J. Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline (vol 272, 246, 2025). JOURNAL OF NEUROLOGY. 2025; 272(5)DOI:10.1007/s00415-025-13077-1. PMID:40285930. IF:4.600(Q1/2D).